Quantitative Molecular Imaging Using PET/CT to Assess Response to Therapy

Similar documents
Typical PET Image. Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located?

AAPM Initiatives in Quantitative Imaging

Identifying Image Artifacts, Their Causes and How to Fix Them: PET. Brad J Kemp, PhD Mayo Clinic, Rochester, MN

Biases affecting tumor uptake measurements in FDG-PET

GE Healthcare. Rad Rx. White Paper

4D PET: promises and limitations

First Clinical Experience with

45 Hr PET Registry Review Course

The Role of PET / CT in Lung Cancer Staging

Metabolic volume measurement (physics and methods)

PET is increasingly being used for diagnosis, staging, and

Positron Emission Tomography in Lung Cancer

PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

Use of molecular and functional imaging for treatment planning The Good, The Bad and The Ugly

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

Biases Affecting the Measurements of Tumor-to-Background Activity Ratio in PET

Integrated PET/CT systems State of the art and Clinical Applications

POSITRON EMISSION TOMOGRAPHY PHANTOM STUDIES FOR RADIATION THERAPY TARGET DELINEATION MICHAEL VINTSON LAWRENCE

Evaluation of Lung Cancer Response: Current Practice and Advances

Reproducibility of Uptake Estimates in FDG PET: a Monte Carlo study

MRI-PET: Oncologic Applications

Radionuclides in Medical Imaging. Danielle Wilson

Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)

Description of the consecutive stages (which took place from December 2002 to July 2003)

Radiation Exposure to Staff Using PET/CT Facility

PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

A Snapshot on Nuclear Cardiac Imaging

Photon Attenuation Correction in Misregistered Cardiac PET/CT

An Introduction to PET Imaging in Oncology

Optimized PET/CT protocols: how much CT is needed? Increasing use of PET-CT. Imaging in Lymphoma

PET/CT for Therapy Assessment in Oncology

Nuclear Medicine and PET. D. J. McMahon rev cewood

Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)

PET in Radiation Therapy. Outline. Tumor Segmentation in PET and in Multimodality Images for Radiation Therapy. 1. Tumor segmentation in PET

Toshiba Aquillion 64 CT Scanner. Phantom Center Periphery Center Periphery Center Periphery

Radiation Detection and Measurement

ESTABLISHING DRLs in PEDIATRIC CT. Keith Strauss, MSc, FAAPM, FACR Cincinnati Children s Hospital University of Cincinnati College of Medicine

PHYSICS 2: HSC COURSE 2 nd edition (Andriessen et al) CHAPTER 20 Radioactivity as a diagnostic tool (pages 394-5)

Standardization of Radiopharmaceutical Dosimetry

PET/CT in Breast Cancer

CLINICAL IMPLEMENTATION OF HYBRID IMAGING CLINICAL IMPLEMENTATION OF HYBRID IMAGING COMBINED IMAGING CLINICAL IMPLEMENTATION OF

Dual-Energy CT: The Technological Approaches

Site Planning and Design of PET/CT Facilities. Melissa C. Martin, M.S., FACR, FAAPM AAPM Annual Meeting, Orlando, FL August 2, 2006

Molecular Imaging and Cancer

Physics of MBI (~10 slides)

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

Clinical PET/CT imaging. PET/CT - Optimization of torso imaging. CT-based attenuation correction. PET/CT torso imaging

IN VIVO IMAGING Proton Beam Range Verification With PET/CT

Imaging Decisions Start Here SM

Repeatability and reproducibility of 18 F-NaF PET quantitative imaging biomarkers

Case 1: 79 yr-old woman with a lump in upper outer quadrant of left breast.

Cardiac PET. John Buscombe

Society of Nuclear Medicine Procedure Guideline for Tumor Imaging Using F-18 FDG

Dual Energy CT Attenuation Correction Methods for Quantitative Assessment of Response to Cancer Therapy with PET/CT Imaging

FDG-18 PET/CT - radiation dose and dose-reduction strategy

Molecular Imaging and Breast Cancer

Quantitative Theranostics in Nuclear Medicine

New Visions in PET: Surgical Decision Making and PET/CT

GUNDERSEN HEATLH SYSTEM NUCLEAR MEDICINE DEPARTMENT PROTOCOL MANUAL

Calculation methods in Hermes Medical Solutions dosimetry software

Quantitation of Cerebral Glucose Utilization using the Arterial Input Function or the Standardized Uptake Value (SUV)

Option D: Medicinal Chemistry

Molecular Imaging and the Brain

X-Ray & CT Physics / Clinical CT

Pitfalls and Remedies in PET/CT imaging for RT planning

SPECT/CT in Endocrine Diseases and Dosimetry

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions

Precision of pre-sirt predictive dosimetry

PET/CT Frequently Asked Questions

Outline. Lifetime Attributable Risk 10 mgy in 100,000 exposed persons (BEIR VII 2006) SPECT/CT and PET/CT Dosimetry

Benefits and Risks of Cancer Imaging

Positron Emission Tomography Computed Tomography (PET/CT)

Ingenuity TF PET/CT. Comfort and quality care in one. Your PET/CT scan with Philips Ingenuity TF PET/CT

WHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?

An audit of radiation dose of 4D CT in a radiotherapy department

Nuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging

Austin Radiological Association BRAIN AMYLOID STUDY (F-18-Florbetapir)

Hybrid systems in Medical Imaging

Theragnostics for bone metastases. Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK

Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT

A. DeWerd. Michael Kissick. Larry. Editors. The Phantoms of Medical. and Health Physics. Devices for Research and Development.

Implementation of the 2012 ACR CT QC Manual in a Community Hospital Setting BRUCE E. HASSELQUIST, PH.D., DABR, DABSNM ASPIRUS WAUSAU HOSPITAL

Simulations of Preclinical andclinical Scans in Emission Tomography, Transmission Tomography and Radiation Therapy. Using GATE

Dosimetry (Dose Estimation) of Internal Emitters. Outline. For Radiation Effects, is Dose the only Answer? Estimation of Dose and not Dosimetry

Principles of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

IAEA RTC. PET/CT and Planning of Radiation Therapy 20/08/2014. Sarajevo (Bosnia & Hercegovina) Tuesday, June :40-12:20 a.

PET Guidance of Therapy for BNCT and in vivo B-10 imaging

Uptake of 18 F-FDG in malignant tumors is subject to

Patterns and Prevalence of Misregistration in 18 F-FDG PET/CT

8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy

PHYS 383: Applications of physics in medicine (offered at the University of Waterloo from Jan 2015)

POSITRON EMISSION TOMOGRAPHY (PET)

María del Pilar Garrido Ruiz Teresa Mendoza Dobaño Cristian Jesús Lucena Morales

ACR MRI Accreditation: Medical Physicist Role in the Application Process

MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES

Nuclear pulmonology. Katalin Zámbó Department of Nuclear Medicine

Transcription:

Quantitative Molecular Imaging Using PET/CT to Assess Response to Therapy Paul Kinahan, PhD Director of PET/CT Physics Imaging Research Laboratory, Department of Radiology University of Washington, Seattle, WA Presented by: Joshua Scheuermann AAPM Annual Meeting July 18-22, 2010 Philadelphia, PA

PET/CT Applications and Challenges Primarily for Cancer Imaging -- works very well Diagnosis and staging Expanding Areas -- with significant challenges Radiation treatment planning using PET and CT Neurological imaging Cardiac imaging Assessment of therapeutic response 2

Do Numbers Matter in PET Images? Elevated uptake of FDG (somehow related to metabolism) The answer to the question Is quantitation necessary for clinical oncological PET studies interpreted by physicians with experience in interpreting PET images? is no. Image quantitation will become increasingly important in determining the effect of therapy in many malignancies. R Edward Coleman Eur J Nucl Med (2002) 29:133 137 3

Imaging FDG uptake (PET) with anatomical localization (CT) and CT-based attenuation correction PET Image of Function Function+Anatomy and CTbased attenuation correction CT Image of Anatomy 4

Response to therapy of liver met gastric GIST No morphological change in the metastasis CT PET/CT Pre therapy 1 wk imatinib therapy PET SUV 5 -> 1.8 Castell and Cook, British Journal of Cancer (2008) 5

Times to Relapse after Neoadjuvant Chemoradiotherapy compared to PET/CT for NSCLC Time to extracerebral progression Partition ratio: SUVmax*(t2)/SUVmax*(t0) 0.5 P < 0.05 Pöttgen, et al Clinical Cancer Research, 2006 6

What do PET scans Measure?

How it works: Positron Emission Radioactive decay unstable atomic nuclei due to too many protons relative to the number of neutrons decays to stable form by converting a proton to a neutron ejects a 'positron' to conserve electric charge positron annihilates with an electron, releasing two anticolinear high-energy photons 18 F 18 n p n O p p p p n n n p n p n p p n p n n p n p p n p p p nn p n n p p n n p p p np p np n ~2 mm β + e - E = mc 2 = 511 kev ~180 deg 8

How it works: Timing coincidence scanner FOV detector A β + + e - annihilation detector B t < 10 ns? record positron decay event reconstruct image of SUV values 9

PET Scans Measure Activity Concentration If everything goes well, the role of the PET scanner is to measure the radioactivity per unit volume Typically measured as kbq/ml or µci/ml 10 mci = 370 MBq inject 70 kg water = 70 L suppose there is a very small object that takes up 5x the local concentration, so its concentration = 26.5 kbq/ml concentration = 370,000 kbq / 70,000 ml = 5.3 kbq/ml 10

What if there are different activities or distribution volumes? Injecting different amounts or changing the volume will change the concentration inject concentration = 5.3 kbq/ml 10 mci = 370 MBq 26.5 kbq/ml 5 mci = 185 MBq 10 mci = 370 MBq inject inject 35 kg = 35 L concentration = 2.8 kbq/ml 13.3 kbq/ml concentration = 10.6 kbq/ml 53.0 kbq/ml The hot spot has different uptake values in kbq/ml even though it has the same relative uptake compared to background 11

Standardized uptake values (SUVs) Normalize by amounts injected per volume (i.e. weight) to get the same relative distribution with SUV = 1.0 for a uniform distribution 10 mci = 370 MBq inject SUV = 5.3 kbq/ml / (370MBq/70 Kg) = 1.0 gm/ml SUV = 5.0 5 mci = 185 MBq inject inject SUV = 1.0 gm/ml SUV = 5.0 SUV = 1.0 gm/ml The hot spot now has the same SUV uptake values independent in activity injected or volume of distribution (i.e. patient size) 10 mci = 370 MBq 35 kg = 35 L SUV = 5.0 12

Measuring uptake: kbq/ml vs SUV Same scale in units of kbq/ml Same scale in units of SUV [g/ml] Liver values look more uniform between patients 13

Sources of Error in SUV Values SUV = PET ROI D INJ / V PET = measured PET activity concentration D' = decay-corrected injected dose V' = surrogate for volume of distribution It is important to minimize SUV errors for serial studies (excluding artifacts) Some potential sources of error are: Determining that blood glucose levels are within range Changing dose uptake time Scanner calibration and cross calibration with dose calibrator Dose assay for each patient, which uses several pieces of information, all of which have to be correct: Correct clock settings for scanners, injection times, and assay times for correct calculations of radioactive decay and dose uptake periods Changing reconstruction or other processing protocols Changing analysis methods: How ROIs are determined and whether max or mean SUV values are reported Weight is typically used as a surrogate for volume of distribution, but can also be further normalized for lean body mass or body surface area, which have to be estimated 14

Biological Effects

Effect of blood [Glu] on SUVs of liver mets from colorectal carcinoma 8 patients w/ 20 liver metastases by CT (size 10-75 mm, mean 32 mm) Fasting FDG-PET scan followed 2 days later by glucose-loaded scan (i.v. glucose infusion (4 mg/kg/min for 2 hr) Fasting scan Glucose loaded [Glu] (mg/100 ml) 92.4 ± 10.2 158 ± 13.8 SUV (all lesions) 9.4 ± 5.7 4.3 ± 8.3 known lesions seen 20/20 14/20 Crippa F. et al. Tumori, 1997 16

Illustration of impact of changes in dose uptake duration 14 Breast tumor FDG uptake vs. time 12 10 8 6 4 2 0 0:00 0:07 0:14 0:21 0:28 0:36 0:43 0:50 0:57 1:04 1:12-2 Injection Time (HH:MM) The same study at different post-injection times will give different SUVs This problem is worse when two different studies are compared looking for an increase or decrease in SUVs between exams Beaulieu JNM 2003 17

Quantitative Corrections

Quantitative errors in measurement no LOR incorrectly determined LORs Compton scatter Lost (attenuated) event Scattered coincidence event Random coincidence event 19

Effects of Attenuation: Patient Study reduced mediastinal uptake 'hot' lungs Nonuniform liver Enhanced skin uptake PET: without attenuation correction PET: with attenuation correction (accurate) CT image (accurate) 20

Scanner Calibration

Effect of ACF calibration error Can not visually see ACF (scanner activity calibration factor) error Incorrect ACF Max SUV = 23.6 Corrected ACF Max SUV = 19.7 Note: Both images scaled to max value 22

Activity Correction Factor Variation in Time 20 10 0 Operator error 18 F 68 Ge Scanner 1 Standard Deviation 68 Ge= 3.2% 18 F = 6.1% Outliers Removed -10 4/20/05 11/6/05 5/25/06 12/11/06 6/29/07 1/15/08 8/2/08 2/18/09 9/6/09 Date 18 F = 4.1% 10% 0% -10% -20% -30% 18 F Operator error 68 Ge 5/10/07 8/18/07 11/26/07 3/5/08 6/13/08 9/21/08 12/30/08 4/9/09 Date Scanner 2 Standard Deviation 68 Ge= 3.1% 18 F = 11.0% Outliers Removed 18 F = 7.0% Lockhart SNM 2009 23

Resolution Effects

Size-Dependent Resolution Losses similar to abdominal x-section Hot sphere diameters of 10, 13, 17, 22, 28, and 37-mm Target/background ratio 4:1 Max and mean activity concentrations measured via 10-mm diameter ROIs Modified NEMA NU-2 IQ Phantom 25

SNM Phantom: Key results of SUV measurements Plots of recovery coefficient (RC) = measured in ROI/true Variations are introduced by the scanner type, acquisition protocol, calibration differences, processing (e.g. image reconstruction method or smoothing) and ROI definition method. averaged coefficients of variation mean SUV: 8.6%, max SUV: 11.1% Kinahan et al 2009 SNM 26

Effect of changing post-reconstruction smoothing 4 mm smoothing 7 mm smoothing 10 mm smoothing SUVmax for 1 cm spheres 3.4 2.1 3.7 3.2 1.6 2.9 SNM Chest phantom, 2 iterations, 28 subsets - True SUV (average) is 4.0 27

Artifacts

Regional Errors (Artifacts) PET-based errors Calibration problems (localized) Detector failures Resolution and partial volume effects Errors from CT-based attenuation correction in PET/CT CT artifacts non-biological objects in patients patient motion truncation 29

Data flow for CT based attenuation correction X-ray acquisition PET Emission Acquisition Smooth to PET Resolution Attenuation Correct PET Emission Data Anatomical (CT) Reconstruction Translate CT to PET Energy (511 kev) Functional (PET) Reconstruction CT Image PET Image Display of PET and CT DICOM image stacks 30

Metal Clip Artifact CT PET with CTAC Courtesy O Mawlawi MDACC 31

Patient and/or bed shifting Large change in attenuation at lung boundaries, so very susceptible to errors PET image without attenuation correction PET image with CT-based attenuation correction (used for measuring SUVs) PET image fused with CT 32

Breathing Artifacts: Propagation of CT breathing artifacts via CT-based attenuation correction Attenuation artifacts can dominate true tracer uptake values 33

Summary of Factors that Influence PET/CT Accuracy and Precision Biological effects: both true uptake (what we want) and biological noise Patient preparation: fasting, glucose levels, uptake period Quantitative corrections: Attenuation, scatter, randoms, detector efficiency normalization Resolution loss: aka partial volume errors Reconstruction method (smoothing and iterations) Analysis method: ROI definition method and SUV mean vs max Artifacts patient motion: respiratory and other incorrect SUV scaling Attenuation correction with CT: truncation, motion, incorrect scaling, general CT artifacts Care should be used if serial studies rely only on lesion SUV values, e.g. monitoring progression of disease 34

Acknowledgements University of Washington Lawrence Macdonald, David Mankoff, Robert Doot SNM Validations Task Force Sandy McEwan, Paul Christian, Joel Karp ACRIN PET Core Lab Joshua Scheuermann, Janet Saffer, Barry Siegal Joint AAPM/SNM Task Group 145 John Boone, Osama Mawlawi, Janet Saffer (ACRIN), Michael McNitt-Gray, Magnus Dahlbom, Ramsey Badawi, Bob Zimmerman, Brian Zimmerman (NIST), Peter Esser (ACR) NCI Cancer Imaging Program / cabig Larry Clarke, Barbara Croft, John Freymann, Justin Kirby, Paula Jacobs RSNA QIBA Dan Sullivan, Richard Frank Pediatric Brain Tumor Consortium Fred Fahey RadQual LLC Keith Allberg Supported by the Society of Nuclear Medicine, the American Association of Physicists in Medicine, R01-CA74135, R01-CA115870CA and NCI Contract 24XS036-004 35